Multiple immunofluorescence assay identifies upregulation of Active β-catenin in prostate cancer
Puig Rosell, Pere (R&D Department, Atrys Health)
Erill, Nadina (R&D Department, Atrys Health)
Terricabras, Marta (R&D Department, Atrys Health)
Subirana, Isaac (R&D Department, Atrys Health)
González-García, Judit (R&D Department, Atrys Health)
Asensi-Puig, Adrià (R&D Department, Atrys Health)
Donovan, Michael J. (Icahn School of Medicine at Mount Sinai, MSSM)
Mengual, Lourdes (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
Agulló-Ortuño, M. Teresa (Instituto de Investigación Hospital. Pathology Department, Urology Department and Laboratory of Translational Oncology)
Olivan, M. (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Alcaraz, Antonio (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
Lopez-Martin, Jose A (Instituto de Investigación Hospital. Pathology Department, Urology Department and Laboratory of Translational Oncology)
de Torres, Inés (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Rodríguez-Peralto, José Luis (Instituto de Investigación Hospital. Pathology Department, Urology Department and Laboratory of Translational Oncology)
Rodríguez-Antolín, Alfredo (Instituto de Investigación Hospital. Pathology Department, Urology Department and Laboratory of Translational Oncology)
Morote Robles, Juan (Hospital Universitari Vall d'Hebron. Institut de Recerca)
González-Rumayor, Víctor (R&D Department, Atrys Health)
Universitat Autònoma de Barcelona
Date: |
2019 |
Abstract: |
To apply a systems pathology-based approach to the quantification of nuclear Active β-catenin and human leukocyte antigen class I, and assess the biomarker involvement in a cohort of prostate tumor patients. The systems pathology approach applied allows a precise quantification of the marker expression in the different cell compartments as well as the determination of the areas that coexpress two markers. Our data shows that the accumulation of β-catenin in the nuclear compartment is significantly decreased in the adjacent normal areas when compared to tumor of the same patients (p < 0. 001). In conclusion, the application of this novel multiple immunofluorescence assay demonstrates that the upregulation of Active β-catenin is a relatively common feature of prostate tumor development, and further supports the activation of the Wnt/β-catenin pathway in prostate cancer progression. The online version of this article (10. 1186/s13104-019-4100-z) contains supplementary material, which is available to authorized users. |
Grants: |
Ministerio de Economía y Competitividad IPT‑2012‑1311‑300000
|
Rights: |
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. |
Language: |
Anglès |
Document: |
Article ; recerca ; Versió publicada |
Subject: |
Active β-catenin ;
HLA class1 ;
Wnt/β-catenin pathway ;
Prostate cancer ;
Systems pathology |
Published in: |
BMC research notes, Vol. 12 (january 2019) , ISSN 1756-0500 |
DOI: 10.1186/s13104-019-4100-z
PMID: 30700322
The record appears in these collections:
Articles >
Research articlesArticles >
Published articles
Record created 2020-07-06, last modified 2024-02-16